

# Kelly E Dunn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8974607/publications.pdf>

Version: 2024-02-01

87  
papers

2,449  
citations

186265  
28  
h-index

243625  
44  
g-index

88  
all docs

88  
docs citations

88  
times ranked

2511  
citing authors

#	ARTICLE	IF	CITATIONS
1	Wireless electroencephalography (EEG) to monitor sleep among patients being withdrawn from opioids: Evidence of feasibility and utility.. <i>Experimental and Clinical Psychopharmacology</i> , 2022, 30, 1016-1023.	1.8	7
2	Evaluation of Stigma Related to Perceived Risk for Coronavirus-19 Transmission Relative to the Other Stigmatized Conditions Opioid Use and Depression. <i>Frontiers in Psychiatry</i> , 2022, 13, 803998.	2.6	1
3	Searching for a Signal: Self-Reported Kratom Dose-Effect Relationships Among a Sample of US Adults With Regular Kratom Use Histories. <i>Frontiers in Pharmacology</i> , 2022, 13, 765917.	3.5	19
4	Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting. <i>American Journal on Addictions</i> , 2022, 31, 256-260.	1.4	3
5	Dopamine Supersensitivity: A Novel Hypothesis of Opioid-Induced Neurobiological Mechanisms Underlying Opioid-Stimulant Co-use and Opioid Relapse. <i>Frontiers in Psychiatry</i> , 2022, 13, 835816.	2.6	6
6	Need for Clarity and Context in Case Reports on Kratom Use, Assessment, and Intervention. <i>Substance Abuse</i> , 2022, 43, 1221-1224.	2.3	8
7	Patient-reported sleep outcomes in randomized-controlled trials in persons with substance use disorders: A systematic review. <i>Drug and Alcohol Dependence</i> , 2022, 237, 109508.	3.2	8
8	Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	23
9	Kratom use as more than a "self-treatment". <i>American Journal of Drug and Alcohol Abuse</i> , 2022, 48, 684-694.	2.1	20
10	Real-time monitoring of cannabis and prescription opioid co-use patterns, analgesic effectiveness, and the opioid-sparing effect of cannabis in individuals with chronic pain. <i>Journal of Pain</i> , 2022, , .	1.4	1
11	Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone. <i>American Journal on Addictions</i> , 2021, 30, 83-87.	1.4	56
12	The association of prefrontal cortex response during a natural reward cue-reactivity paradigm, anhedonia, and demoralization in persons maintained on methadone. <i>Addictive Behaviors</i> , 2021, 113, 106673.	3.0	14
13	Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic. <i>Journal of Substance Abuse Treatment</i> , 2021, 121, 108197.	2.8	27
14	Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108649.	3.2	3
15	Early Life Stress and Risks for Opioid Misuse: Review of Data Supporting Neurobiological Underpinnings. <i>Journal of Personalized Medicine</i> , 2021, 11, 315.	2.5	9
16	Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model. <i>Neuropsychopharmacology</i> , 2021, 46, 1451-1459.	5.4	17
17	The discounting of death: Probability discounting of heroin use by fatal overdose likelihood and drug purity.. <i>Experimental and Clinical Psychopharmacology</i> , 2021, 29, 219-228.	1.8	5
18	Use of an electronic pillbox to increase number of methadone take-home doses during the COVID-19 pandemic. <i>Journal of Substance Abuse Treatment</i> , 2021, 126, 108328.	2.8	13

#	ARTICLE	IF	CITATIONS
19	The continued rise of methamphetamine use among people who use heroin in the United States. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108750.	3.2	33
20	Feasibility and acceptability of using smartphone-based EMA to assess patterns of prescription opioid and medical cannabis use among individuals with chronic pain. <i>Internet Interventions</i> , 2021, 26, 100460.	2.7	9
21	Establishing preclinical withdrawal syndrome symptomatology following heroin self-administration in male and female rats.. <i>Experimental and Clinical Psychopharmacology</i> , 2021, 29, 636-649.	1.8	18
22	Attitudes Toward Organ Donation for Persons Who Have a Substance Use Disorder Relative to Other Health Conditions. <i>Frontiers in Psychiatry</i> , 2021, 12, 698645.	2.6	0
23	Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D. <i>Journal of Addiction Medicine</i> , 2021, 15, 325-333.	2.6	3
24	Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes. <i>Addiction Biology</i> , 2020, 25, e12680.	2.6	30
25	Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108212.	3.2	8
26	Challenges for Women Entering Treatment for Opioid Use Disorder. <i>Current Psychiatry Reports</i> , 2020, 22, 76.	4.5	32
27	Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States. <i>JAMA Network Open</i> , 2020, 3, e1920843.	5.9	55
28	Evaluating the co-use of opioids and cannabis for pain among current users using hypothetical purchase tasks. <i>Journal of Psychopharmacology</i> , 2020, 34, 654-662.	4.0	12
29	The impact of naturalistic cannabis use on self-reported opioid withdrawal. <i>Journal of Substance Abuse Treatment</i> , 2020, 113, 108005.	2.8	15
30	Kratom ( <i>Mitragyna speciosa</i> ): User demographics, use patterns, and implications for the opioid epidemic. <i>Drug and Alcohol Dependence</i> , 2020, 208, 107849.	3.2	98
31	Gabapentin Enacarbil Extendedâ€Release for Alcohol Use Disorder: A Randomized, Doubleâ€Blind, Placeboâ€Controlled, Multisite Trial Assessing Efficacy and Safety. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 158-169.	2.4	60
32	The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal. <i>Drug and Alcohol Dependence</i> , 2019, 202, 111-114.	3.2	5
33	Buprenorphine in the United States: Motives for abuse, misuse, and diversion. <i>Journal of Substance Abuse Treatment</i> , 2019, 104, 148-157.	2.8	73
34	A Systematic Review of Laboratory Evidence for the Abuse Potential of Tramadol in Humans. <i>Frontiers in Psychiatry</i> , 2019, 10, 704.	2.6	34
35	Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 422-452.	2.5	39
36	Increased neural activity in the right dorsolateral prefrontal cortex during a risky decision-making task is associated with cocaine use in methadone-maintained patients. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107650.	3.2	12

#	ARTICLE	IF	CITATIONS
37	Review: Sex-Based Differences in Treatment Outcomes for Persons With Opioid Use Disorder. <i>American Journal on Addictions</i> , 2019, 28, 246-261.	1.4	71
38	Randomized comparison of two web-based interventions on immediate and 30-day opioid overdose knowledge in three unique risk groups. <i>Preventive Medicine</i> , 2019, 128, 105718.	3.4	16
39	Individuals with Chronic Pain Who Misuse Prescription Opioids Report Sex-Based Differences in Pain and Opioid Withdrawal. <i>Pain Medicine</i> , 2019, 20, 1942-1947.	1.9	21
40	Individual differences in human opioid abuse potential as observed in a human laboratory study. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107688.	3.2	8
41	Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use. <i>Journal of Addiction Medicine</i> , 2019, 13, 300-305.	2.6	12
42	Differential adoption of opioid agonist treatments in detoxification and outpatient settings. <i>Journal of Substance Abuse Treatment</i> , 2019, 107, 24-28.	2.8	13
43	Prefrontal cortex response to drug cues, craving, and current depressive symptoms are associated with treatment outcomes in methadone-maintained patients. <i>Neuropsychopharmacology</i> , 2019, 44, 826-833.	5.4	35
44	Characterizing the subjective, observer-rated, and physiological effects of hydromorphone relative to heroin in a human laboratory study. <i>Psychopharmacology</i> , 2018, 235, 971-981.	3.1	9
45	Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT. <i>Journal of Substance Abuse Treatment</i> , 2018, 85, 31-33.	2.8	1
46	Tramadol Extended-Release and Opioid Withdrawal Management—Legal Implications—Reply. <i>JAMA Psychiatry</i> , 2018, 75, 215.	11.0	0
47	Naloxone formulation for overdose reversal preference among patients receiving opioids for pain management. <i>Addictive Behaviors</i> , 2018, 86, 56-60.	3.0	18
48	Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients. <i>Addictive Behaviors</i> , 2018, 76, 8-14.	3.0	49
49	The risk for problematic opioid use in chronic pain: What can we learn from studies of pain and reward?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 87, 255-262.	4.8	19
50	Systematic review of sex-based differences in opioid-based effects. <i>International Review of Psychiatry</i> , 2018, 30, 107-116.	2.8	35
51	Promoting a comprehensive understanding of the opioid epidemic. <i>International Review of Psychiatry</i> , 2018, 30, 89-90.	2.8	1
52	A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2018, 193, 142-147.	3.2	80
53	Opioid Overdose Education for Individuals Prescribed Opioids for Pain Management: Randomized Comparison of Two Computer-Based Interventions. <i>Frontiers in Psychiatry</i> , 2018, 9, 34.	2.6	27
54	Pain as a predictor and consequence of tobacco abstinence effects amongst African American smokers.. <i>Journal of Abnormal Psychology</i> , 2018, 127, 683-694.	1.9	11

#	ARTICLE	IF	CITATIONS
55	Opioid Overdose History, Risk Behaviors, and Knowledge in Patients Taking Prescribed Opioids for Chronic Pain. <i>Pain Medicine</i> , 2017, 18, pnw228.	1.9	19
56	Why aren't physicians prescribing more buprenorphine?. <i>Journal of Substance Abuse Treatment</i> , 2017, 78, 1-7.	2.8	212
57	Randomized controlled trial of a computerized opioid overdose education intervention. <i>Drug and Alcohol Dependence</i> , 2017, 173, S39-S47.	3.2	30
58	Effects of incentives for naltrexone adherence on opiate abstinence in heroin-dependent adults. <i>Addiction</i> , 2017, 112, 830-837.	3.3	19
59	The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use. <i>Drug and Alcohol Dependence</i> , 2017, 180, 279-285.	3.2	37
60	Efficacy of Tramadol Extended-Release for Opioid Withdrawal. <i>JAMA Psychiatry</i> , 2017, 74, 885.	11.0	42
61	Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence. <i>Alcohol and Alcoholism</i> , 2017, 52, 72-79.	1.6	7
62	A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence. <i>Neuropsychopharmacology</i> , 2017, 42, 1012-1023.	5.4	61
63	Behavioral risk assessment for infectious diseases (BRAID): Self-report instrument to assess injection and noninjection risk behaviors in substance users. <i>Drug and Alcohol Dependence</i> , 2016, 168, 69-75.	3.2	10
64	Opioid Overdose Experience, Risk Behaviors, and Knowledge in Drug Users from a Rural Versus an Urban Setting. <i>Journal of Substance Abuse Treatment</i> , 2016, 71, 1-7.	2.8	47
65	Brief Opioid Overdose Knowledge (BOOK): A Questionnaire to Assess Overdose Knowledge in Individuals Who Use Illicit or Prescribed Opioids. <i>Journal of Addiction Medicine</i> , 2016, 10, 314-323.	2.6	45
66	Measures of outcome for stimulant trials: ACTION recommendations and research agenda. <i>Drug and Alcohol Dependence</i> , 2016, 158, 1-7.	3.2	49
67	Comparison of methods to assess psychiatric medication adherence in methadone-maintained patients with co-occurring psychiatric disorder. <i>Drug and Alcohol Dependence</i> , 2016, 160, 212-217.	3.2	7
68	Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation. <i>Nicotine and Tobacco Research</i> , 2016, 18, 1171-1179.	2.6	11
69	Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes.. <i>Psychology of Addictive Behaviors</i> , 2015, 29, 270-276.	2.1	15
70	Characterizing opioid withdrawal during double-blind buprenorphine detoxification. <i>Drug and Alcohol Dependence</i> , 2015, 151, 47-55.	3.2	26
71	Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients. <i>Drug and Alcohol Dependence</i> , 2015, 157, 143-149.	3.2	41
72	Severity and Interference of Chronic Pain in Methadone-Maintained Outpatients. <i>Pain Medicine</i> , 2014, 15, 1540-1548.	1.9	57

#	ARTICLE	IF	CITATIONS
73	Characterizing smoking, cessation services, and quit interest across outpatient substance abuse treatment modalities. <i>Journal of Substance Abuse Treatment</i> , 2014, 46, 194-201.	2.8	40
74	Spontaneous reductions in smoking during double-blind buprenorphine detoxification. <i>Addictive Behaviors</i> , 2014, 39, 1353-1356.	3.0	10
75	Employment-based abstinence reinforcement following inpatient detoxification in HIV-positive opioid and/or cocaine-dependent patients.. <i>Experimental and Clinical Psychopharmacology</i> , 2014, 22, 75-85.	1.8	5
76	Characterizing and improving HIV and hepatitis knowledge among primary prescription opioid abusers. <i>Drug and Alcohol Dependence</i> , 2013, 133, 625-632.	3.2	20
77	Characterizing and improving HIV/AIDS knowledge among cocaine-dependent outpatients using modified materials. <i>Drug and Alcohol Dependence</i> , 2013, 127, 220-225.	3.2	13
78	A Randomized, Double-blind Evaluation of Buprenorphine Taper Duration in Primary Prescription Opioid Abusers. <i>JAMA Psychiatry</i> , 2013, 70, 1347.	11.0	72
79	Pretreatment Alcohol Drinking Goals are Associated with Treatment Outcomes. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1745-1752.	2.4	68
80	Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users.. <i>Experimental and Clinical Psychopharmacology</i> , 2013, 21, 74-83.	1.8	41
81	The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: A review. <i>Drug and Alcohol Dependence</i> , 2011, 119, 1-9.	3.2	53
82	Contingency management for behavior change: Applications to promote brief smoking cessation among opioid-maintained patients.. <i>Experimental and Clinical Psychopharmacology</i> , 2011, 19, 20-30.	1.8	13
83	A contingency-management intervention to promote initial smoking cessation among opioid-maintained patients.. <i>Experimental and Clinical Psychopharmacology</i> , 2010, 18, 37-50.	1.8	61
84	Brief buprenorphine detoxification for the treatment of prescription opioid dependence: A pilot study. <i>Addictive Behaviors</i> , 2009, 34, 304-311.	3.0	27
85	Effects of Smoking Cessation on Illicit Drug Use among Opioid Maintenance Patients: A Pilot Study. <i>Journal of Drug Issues</i> , 2009, 39, 313-327.	1.2	13
86	Evaluation of ongoing oxycodone abuse among methadone-maintained patients. <i>Journal of Substance Abuse Treatment</i> , 2008, 35, 451-456.	2.8	17
87	VOUCHER-BASED CONTINGENT REINFORCEMENT OF SMOKING ABSTINENCE AMONG METHADONE-MAINTAINED PATIENTS: A PILOT STUDY. <i>Journal of Applied Behavior Analysis</i> , 2008, 41, 527-538.	2.7	58